E
Equillium D
D
EQ
1.15000
USD
0.17
(17.48%)
مغلق
حجم التداول
126,839
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
41,077,215
العنوان: Equillium
القطاع: Healthcare
الصناعة: Biotechnology
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.